/
PMCB
$0.55+$0.00 (+0.47%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$5.9M
11M shares
52-week range
$0.53 – $1.51
2% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-2.41
PharmaCyte Biotech, Inc. Common Stock
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
pharmacyte.com- Employees
- 2
- IPO / List date
- Sep 11, 2003
- HQ
- LAS VEGAS, NV
Held by traders on TradeandTell
No one on the platform currently holds PMCB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 56,500 | $37.6K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2021-07-12 | 1-for-1500reverse |
| 2003-12-08 | 3-for-1 |
Recent trades on TradeandTell
No one on the platform has traded PMCB yet.
